Listonstreetpulse.com announces that Arrayit Corporation (OTC: ARYC) has quoted a $131,250 services contract to a leading East Coast USA pharmaceutical company for Phase 1 drug compound validation using the company’s patented and proprietary biomarker discovery and pharmaceutical benchmarking engine.
Arrayit offers full service genetic disease analysis, biomarker discovery, and therapeutic protein and drug compound validation using its genomic, transcriptomic, and proteomic profiling core competencies. The five phase services program is priced from $131K to $6.3 million based on the number of samples processed and the scope of the services. Arrayit customers submit mRNA samples from human cells treated with proprietary drug compounds and from controls treated with saline buffer.
Arrayit performs comparative, comprehensive genomic expression profiling analysis using its H25K Whole Human Genome Chips, which measure the expression of every gene in the human body and identify genes that are activated or repressed by drug treatment. Genomic expression data are loaded into high-speed computers and modeled using Arrayit Genome Pathway Builder™ software to identify the cellular pathway targeted by the therapeutic compound.
Arrayit microarray technology offers the highest sensitivity and specificity on the market, which gives pharmaceutical clients a competitive advantage in the marketplace by streamlining drug discovery and improving the outcome of clinical trials. Arrayit-identified biomarkers can also be used for companion diagnostics to screen the patient population for responders and non-responders after FDA approval of a blockbuster medicine. ARYC plans to increasingly address the global drug sales market, which according to Reuters, is expected to exceed $1.1 trillion in 2014.
To read more about ARYC and subscribe to a monthly update, CEO interview etc, please click here – http://www.listonstreetpulse.com/tag/ARYC/
About Arrayit Corporation
Arrayit Corporation is a Sunnyvale, California-based company leading and empowering the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development, and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. The company’s innovative products and services help scientists and clinicians explore the human genome as well as the genomes of plants and animals. Arrayit’s products are used by every major research center in the world.
About Liston Street Pulse
Liston Street Pulse is a leading provider of financial research. The company has significant expertise in U.S. listed small cap and micro-cap stocks. Over the years, Liston Street Pulse’s original and unbiased analysis has helped the investor community immensely.
###
